Market Overview

UPDATE: Collins Stewart Downgrades Human Genome Sciences to Neutral


Collins Stewart lowers its rating on Human Genome Sciences (NASDAQ: HGSI) to Neutral, as survey suggests lackluster performance in 2012. Target price is at $10.

Collins Stewart says, "We are presenting the results of our 4Q11 Benlysta tracking survey (N=30), which suggests that 83% of physicians expect to treat an average of 4.6 patients by mid-2012 and 87% expect to treat an average of 11 by YE12 (vs. 53% treating 5.1 in Dec). ...With HGSI shares up 15% YTD (vs. NBI +12%) and concerns on HGSI's ability to meet FY12+ Benlysta estimates, we are downgrading to Neutral and lowering our PT to $10 from $17."

HGSI closed at $8.36 a share on Wednesday.


Related Articles (HGSI)

View Comments and Join the Discussion!

Posted-In: Collins StewartAnalyst Color Downgrades Price Target Pre-Market Outlook Analyst Ratings

Latest Ratings

IBIOCantor FitzgeraldInitiates Coverage On3.0
UPLDCanaccord GenuityMaintains57.0
EJefferiesInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at